Unichem’s foray into the Americas includes USA, Canada, Brazil, and other Latin American markets, where it aspires to become a major player by offering high quality and cost-effective generic products. A majority of the company’s products are vertically integrated. Unichem’s R&D team is actively developing a robust pipeline of Active Pharmaceutical Ingredients (APIs) and ANDAs to support its ambitious growth plans.
United States of America (USA)
In the USA, Unichem markets a growing list of USFDA approved products through its wholly owned subsidiary, Unichem Pharmaceuticals Inc. The company has several USFDA approved Abbreviated New Drug Applications (ANDAs) and continues to file new Drug Master Files (DMFs) and ANDAs for USFDA approval and launch in the US market.
Unichem’s wholly owned subsidiary, Unichem Farmaceutica do Brasil Ltda., focuses on the growing demand for generic products in Brazil, and is currently marketing several ANVISA approved products. The company has filed new product dossiers for ANVISA approval with several more in the development pipeline. Unichem is set to aggressively develop and grow its business in Brazil and has formed distribution and marketing alliances with key players in other Latin American markets.
Unichem markets its generic formulations in Canada through product development and supply agreements with leading Canadian generic pharmaceutical companies.